Gene editing trial starts since 2023: Sickle cell disease or beta-thalassaemia
RecordSTO-YE8M0BS1N7-C48ATWDF3X-275NMW
Global · 1 Jan 2023 to 27 Sep 2026
Gene editing trial starts since 2023: Sickle cell disease or beta-thalassaemia worldwide was 18 between 1 January 2023 and 27 September 2026 (ClinicalTrials.gov).
- Publisher
- ClinicalTrials.gov
- Authority tier
- T1 Official
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27.
- Retrieved
- 27 Sep 2026
- Status
- Verified
What the source says
{"totalCount":18,"studies":[
Checked: the figure 18 is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=sickle%20OR%20thalassemia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_YE8M0BS1N7C48ATWDF3X275NMW
Other formats: MLA, Chicago, BibTeX
- MLA
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27." 2026, https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=sickle%20OR%20thalassemia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_YE8M0BS1N7C48ATWDF3X275NMW.
- Chicago
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27." 2026. https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&query.cond=sickle%20OR%20thalassemia&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_YE8M0BS1N7C48ATWDF3X275NMW.
- BibTeX
- @misc{clinicaltrialsgo2026ctgov275nmw, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_YE8M0BS1N7C48ATWDF3X275NMW}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR\%20OR\%20Cas9\%20OR\%20Cas12\%20OR\%20\%22base\%20editing\%22\%20OR\%20\%22base\%20editor\%22\%20OR\%20\%22prime\%20editing\%22\%20OR\%20\%22gene\%20editing\%22\%20OR\%20\%22genome\%20editing\%22\%20OR\%20\%22zinc\%20finger\%20nuclease\%22\%20OR\%20TALEN\%20OR\%20exagamglogene\%20OR\%20NTLA-2001\%20OR\%20NTLA-2002\%20OR\%20nexiguran\%20OR\%20lonvoguran\%20OR\%20VERVE-101\%20OR\%20VERVE-102\%20OR\%20BEAM-101\%20OR\%20BEAM-302\%20OR\%20EBT-101\%20OR\%20EDIT-101\%20OR\%20CTX310\%20OR\%20\%22epigenetic\%20editing\%22\%20OR\%20CTX320\%20OR\%20YOLT-101\%20OR\%20YOLT-201\%20OR\%20ART001\%20OR\%20CS-101\&query.cond=sickle\%20OR\%20thalassemia\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2023-01-01\%2C2026-09-27\%5D\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27
- Type
- Dataset
- Published
- —
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27.
- Retrieved
- 27 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- Public domain
Verification
- Status
- Verified
- Review protocol
- pipeline:ctgov-api-totalcount-verified
- Checked on
- 27 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_YE8M0BS1N7C48ATWDF3X275NMW